Based on the predicament of the scarcity of clinical drugs for breast cancer and the potential of targeting AGK in the treatment of breast cancer, this study employed a structure-based drug screening strategy that integrates in vitro cell lines and subcutaneous tumor models in nude mice to identify potential marketed drugs targeting AGK, with the aim of providing survival benefits for breast cancer patients. This evidence concerns the gene AGK and breast carcinoma.